Published Reported
Marius Pharmaceuticals applauds FDA’s proposed testosterone labeling updates as a turning point for men’s health
A cardiovascular outcomes trial of more than 5,200 men found no meaningful increase in major adverse cardiovascular events, and testosterone deficiency is a widespread, undertreated condition.